1YBottom 25% of the group
Rank 51 of 63 funds
Return +16.68%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 51No. 1 is SCBGENOME(E) +68.99%
Krungsri Global Healthcare Equity Hedged FX Fund
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
KFHHCARE-D invests through the master fund JPMorgan Funds - Global Healthcare Fund 99.62%
This fundKFHHCARE-D
The fund that actually investsJPMorgan Funds - Global Healthcare FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY7.97%
ABBVIE ABBV7.27%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per JPMorgan fact sheet
Over the past year it was in the bottom 25% of its group; over 5 years it returned −0.27% per year (Below half the group)
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.35% | +3.39% | +5.07% | +11.69% | +9.16% | +17.52% | +16.68% | +24.26% | −1.34% | +44.97% | +49.14% |
Total return over each period, matching the NAV chart periods · Not annualised
Largest drawdown in the selected period −26.66% Previous peak 20 Feb 2020 (NAV 8.6097) → Trough 23 Mar 2020 (NAV 6.3146) · Back to the previous peak on 23 Jun 2020, after 3 months
Currently −1.34% from the peak NAV of 11.0592 (4 Nov 2021)
Over 5 years, KFHHCARE-D returned -0.02 per unit of volatility, ranking 18 of 33 funds · The highest is FP HCARE-A (0.44)
Paid 3 times in the past 12 months, totalling 0.6500 THB per unit, or 5.96% of NAV
KFHHCARE-D pays cash dividends to unitholders from part of the fund's profit. Below is a summary of when you get paid, how much, and how regularly
THB/unit, totalled by year of payment · * 2026 to 4 Nov 2026
Based on NAV 9.9623 → 10.9106 THB (4 Nov 2025 – 4 Nov 2026) and dividends over the same period
Unitholders' total value doesn't disappear. Part of it moves from the NAV into cash (the example assumes asset prices don't change that day) · See the D markers on the NAV chart
กองทุนจะลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศที่มีเป้าหมายให้ผลตอบแทนในการถือครองหน่วยลงทุนในระยะยาว โดยจะลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว โดยเฉลี่ยในรอบปีบัญชีไม่ต่ำกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน ชื่อ JPMorgan Funds - Global Healthcare Fund, Class: JPM… Its largest holdings are Eli Lilly 7.80% · AbbVie 6.90% · Johnson & Johnson 6.10% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 31 Jan 2019, its NAV has fallen as much as −26.66% from its peak.
Actual total expense ratio (TER) 1.54% a year, against a ceiling of 4.65%. Management fee 1.34%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
Yes. The latest was 0.1500 THB per unit, book close 4 Sep 2026, paid 15 Sep 2026 · 10 payments so far, totalling 3.5700 THB per unit. Dividends are subject to 10% withholding tax and are not guaranteed
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 14:30, and redemption proceeds are paid T+4
Almost fully hedged. As of 30 Sep 2026, 100.28% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · KFHHCARE-D: pays dividends, TER 1.54% · KFHHCARE-A: no dividends, TER 1.54% · KFHHCARE-I: no dividends, TER 1.54%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Merck & MRK5.28%
Thermo Fisher TMO4.58%
Novartis NOVN4.48%
AstraZeneca AZN.L4.08%
Unitedhealth Group UNH3.29%
Abbott Laboratories ABT2.89%
Danaher DHR2.89%Eli Lilly and Co LLYDiabetes and weight-loss drugs
ABBVIE ABBVHospitals, medicines and medical equipment
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Merck & MRKHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Danaher DHRHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (99.62% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from JPMorgan · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +22.37% per year
No. 1 is FP HCARE-A +6.71% per year
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.1 | +0.3 | −6.5 | −0.7 | +2.3 | +6.1 | −1.0 | +2.8 | −2.5 | +8.1 | +1.0 | · | +9.4* |
| 2025 | +7.9 | −1.3 | −3.4 | −2.9 | −4.4 | +1.7 | −0.7 | +2.4 | +0.3 | +5.2 | +7.5 | −1.4 | +10.7 |
| 2024 | +1.8 | +2.9 | +1.8 | −3.9 | +0.3 | +2.7 | +1.7 | +4.6 | −4.6 | −4.2 | −1.2 | −7.7 | −6.5 |
| 2023 | −0.8 | −2.3 | +1.3 | +1.5 | −4.3 | +3.7 | +0.6 | −0.4 | −5.1 | −7.3 | +5.8 | +7.3 | −1.2 |
| 2022 | −9.9 | +0.9 | +7.6 | −6.7 | −2.5 | −1.5 | +4.4 | −3.2 | −3.0 | +3.8 | +1.5 | −1.2 | −10.5 |
THB/unit by book-close date
0 of 10 book-close dates match the SEC dividend history · The rest are inferred from the dates NAV fell by the dividend amount
